Media Database
>
Caitlin Mollison

Caitlin Mollison

Managing Editor at Pharmacy Times

Contact this person
Email address
c*****@*******.comGet email address
Influence score
48
Phone
(XXX) XXX-XXXX Get mobile number
Location
United States
Languages
  • English
Covering topics
  • Health & Medicine

View more media outlets and journalists by signing up to Prowly

View latest data and reach out all from one place
Sign up for free

Recent Articles

pharmacytimes.com

Pharmacists Are Moderately Satisfied With Compensation, Slightly ... - Pharmacy Times

A total of 150 respondents rated their satisfaction with total annual compensation as 4.15 on a scale of 1 to 7, down from 4.41 in 2021.
pharmacytimes.com

Investigators Identify Compound That May Halt Infections, Including...

Findings from the University of British Columbia’s Life Sciences Institute show a potential path toward antiviral treatments that could be used against many different pathogens.
pharmacytimes.com

Study Results Assess Neoadjuvant Olaparib/Paclitaxel vs ... - Pharm...

Long-term data showed no difference in the clinical benefit between the treatments for HER2-negative early breast cancer with homologous recombination deficiency.
pharmacytimes.com

Capivasertib Plus Fulvestrant Improves PFS in Those With ... - Phar...

Results from the phase 3 CAPItello-291 clinical trial show that the combination doubled the median progression-free survival compared with the placebo in patients with HR-positive, HER2-negative advanced breast cancer.
pharmacytimes.com

Final Analysis of MONARCH 2 Trial Results Confirms Overall ... - Ph...

The phase 3 clinical trial shows that the 5-year OS for patients with HR+/HER2- advanced breast cancer in the abemaciclib plus fulvestrant group was 41.2% vs 29.2% for the placebo arm.
pharmacytimes.com

Real World Testing May Help Better Understand Inconsistent ... - Ph...

Dawn L. Hershman, MD, MS, Columbia University Medical Center, New York, NY, presents her findings at the 2022 San Antonio Breast Cancer Symposium.
pharmacytimes.com

Metformin Meets Primary Endpoint in Study of ALP-Induced ... - Phar...

Efficacy and safety profile in combination with alpelisib is comparable to that reported in the BYLieve and SOLAR-1 clinical trials, according to a poster presentation at the San Antonio Breast Cancer Symposium.
pharmacytimes.com

New Drug Could Change Treatment Landscape for ER-Positive ... - Pha...

Researchers discovered the most common single gene mutation that causes treatment-resistance in first- line ER-positive or HER2-negative breast cancer treatment with a CDK4/6 inhibitor.
pharmacytimes.com

Trastuzumab Deruxtecan Outperforms T-DM1 in Overall Survival for .....

Clinical trial results found that second-line treatment with trastuzumab deruxtecan led to significantly longer overall survival compared with trastuzumab emtansine.
pharmacytimes.com

Interim Analysis Updates Adjuvant Abemaciclib Plus Endocrine ... - ...

Phase 3 monarchE trial assesses distant relapse free-survival, invasive disease-free survival, and overall survival for the treatment of HR-positive/HER2-negative-, node-positive, high-risk early breast cancer.
pharmacytimes.com

Black Women With Breast Cancer Show Worse Outcomes Than Peers

RxPonder clinical trial results indicate that racial disparities continue to be a major health care challenge.